The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
The conversation is about comparing the effectiveness of 5% RU58841 and 0.5% pyrilutamide for hair loss treatment. The user is asking if the higher concentration of RU58841 makes it stronger than the lower dose of pyrilutamide.
Pyrilutamide shows minimal systemic absorption with low plasma levels and no accumulation, suggesting it's unlikely to cause systemic side effects. However, full results are not yet published in scientific journals.
Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.
The user experienced facial puffiness after switching from finasteride to dutasteride, which they believe is due to dutasteride. They are seeking advice on reversing this effect, considering factors like diet, exercise, and potential hormonal changes.
The potential release date for results from a phase 2 trial of Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841. It was agreed that the results are expected to be released in June 2022.
VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.
The conversation is about the correct way to do microneedling for hair loss, with some users suggesting the user is pressing too hard and causing too much bleeding, while others think the amount of blood is fine. Specific treatments mentioned include microneedling, with advice to disinfect the roller and possibly use a shorter needle length.
Dutasteride effectively reduces DHT levels and significantly increases testosterone levels. Users are cautious about adding oral minoxidil due to potential heart issues and are considering dosage adjustments with medical guidance.
Oral minoxidil may cause heart palpitations, especially in those sensitive to caffeine. It's advised to consult a doctor and consider starting at a low dose or using topical minoxidil.
The user has been using a hair loss treatment regimen including RU58841, minoxidil, and dutasteride, but still experiences hairline recession and fatigue despite high testosterone levels. They are considering adjusting their dutasteride dosage due to concerns about libido and energy levels.
Minoxidil caused side effects like chest pain and tinnitus for the user, leading them to stop using it and consider switching to finasteride with microneedling. Other users shared similar experiences with minoxidil, while some reported no issues, highlighting varied individual reactions.
Pyrilutimide, a treatment for hair loss; it's effectiveness compared to other treatments such as Finasteride and RU58841; and some users’ experiences with the treatment.
Treating hair loss with finasteride, dutasteride and minoxidil, as well as micro-needling, potentially using research chemicals such as Pyril and Senzu Beans.
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.
Peppermint Essential Oil (PEO) was discussed for its hair regrowth effects on shaved mice after 4 weeks. Specific treatments mentioned include Minoxidil (Min), Finasteride (Fin), and RU58841 (RU).
Oral minoxidil is generally effective for hair loss but may cause side effects like heart palpitations and facial puffiness. Users highlight the importance of monitoring blood pressure due to potential cardiovascular risks.
The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.
Dutasteride is hard to get in Europe due to prescription rules, leading some to consider online pharmacies or travel. Users discuss alternatives like private doctors and compare it to finasteride, expressing concerns about side effects and effectiveness.
People are discussing the use of finasteride for hair loss and the importance of hormonal blood testing to monitor effects like changes in DHT and estradiol levels. Some users also mention using minoxidil and the potential side effects of estradiol, such as gynecomastia, especially at higher doses.
The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.
The conversation discusses switching from a dermaroller to a dermastamp for microneedling, with recommendations on technique and frequency to avoid bleeding. The user also uses minoxidil and dutasteride for hair loss treatment.
The user experienced heart palpitations from using Fin (0.1%) and Min (10%) and is seeking alternatives. Options suggested include PRP or Mesotherapy, with a recommendation to try topical Fin without Min.